New hope for kids with tough cancers: first trial of a novel cell therapy
NCT ID NCT04897321
Summary
This is a first-in-human study testing a new type of personalized cell therapy for children and young adults (up to age 21) whose solid tumors have come back or haven't responded to standard treatments. Doctors will collect a patient's own immune cells (T cells), genetically modify them in a lab to target a protein called B7-H3 found on many solid tumors, and then infuse them back into the patient. The main goal of this early-phase trial is to find the safest dose of these modified cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.